Canbridge Pharmaceuticals Inc. · HKEX:1228
Canbridge Pharmaceuticals — FY2021 Earnings Presentation
30 slides from Canbridge Pharmaceuticals's earnings presentation, Mar 23, 2022
Slide 1: FY2021 Annual Results Presentation
Slide Title CANbridge Pharmaceuticals FY2021 Annual Results Presentation March 2022
Slide 2: Disclaimer
Disclaimer THIS DOCUMENT OR THE INFORMATION CONTAINED HEREIN IS NOT INTENDED TO AND DOES NOT CONSTITUTE ANY OFFER OR INVITATION, SOLICITATION, COMMITMENT OR ADVERTISEMENT OF ANY OFFER FOR Slide Title SUBSCRIPTION, PURHCASE OR SALE OF ANY SECURITIES, NOR SHALL ANY PART OF THIS DOCUMENT FORM THE BASIS
Slide 3: Our Vision
Our Vision Slide Title To be a Global Biopharmaceutical Company Delivering Life-changing Therapies to Patients Built Upon a Foundation in China 3
Slide 4: Business Overview
Slide Title 01 Business Overview 4
Slide 5: CANbridge at a Glance
CANbridge at a Glance We are a leading developer of rare disease treatments for the Chinese and global markets, committed to the research, development and Slide Title of innovative therapies with massive market potential commercialization Comprehensive Pipeline with Significant Revenue A Pioneer in
Slide 6: Our Comprehensive and Diversified Pipeline
Our Comprehensive and Diversified Pipeline A portfolio of biologics, small molecules and gene therapy solutions with validated mechanisms of action, targeting some of the most prevalent rare diseases and rare Slide Titlewith significant market potential. CANbridge owns global rights for 7 of the 13
Slide 7: Developing a Gene Therapy Portfolio with Potential Best-in-Class Global Assets
Developing a Gene Therapy Portfolio with Potential Best-in-Class Global Assets Gene therapy holds the promise to transform treatments for LSDs and neuromuscular diseases from ameliorative to curative Slide Title In-licensed Gene Therapy Programs and In-house Tech Platform Pipeline Candidate Discover
Slide 8: Pipeline Targets Diseases with Significant Revenue Potential
Pipeline Targets Diseases with Significant Revenue Potential De-risked pipeline with multiple programs in therapeutics with clinically validated MoAs Slide Title Prevalence Hemo- GBM 55k MPS II 8k 120k PNH 24k gMG 234k Greater China philia A CAN0081 Hunterase® 629 CAN105 2,344 CAN106 CAN106 Global S
Slide 9: Experienced Management Team
Experienced Management Team Strong global management team with deep industry experience and a track record of commercializing rare disease treatments Slide Title • Veteran entrepreneur with 22+ years of experience • 21 years of biotechnology executive management • 15+ years of extensive banking, inv
Slide 10: Business Highlights in 2021
Business Highlights in 2021 Slide Title CAN008 • IND application amended to allow CAN008 to be studied as a first- line Phase II trial Initiated a Phase II trial in China in April 2021 and dosed the first patient in October Corporate and Business Development • FY2021 net revenue RMB 31.2M, mainly at
Slide 11: Pipeline Update
Slide Title 02 Pipeline Update 11
Slide 12: CAN008 – CD95-Fc Fusion Protein for Glioblastoma Multiforme (GBM)
CAN008 – CD95-Fc Fusion Protein for Glioblastoma Multiforme (GBM) CAN008 is in clinical development as a first-line therapy for GBM in China Slide Title Obtained exclusive rights to develop, manufacture and CD95L binds to its receptor, CD95, on the cell surface Mechanism of Action commercialize CAN0
Slide 13: CAN008 – Phase Data and Phase Design
CAN008 – Phase 1 Data and Phase 2 Design Encouraging Phase 1 Data in newly diagnosed GBM1 Slide Title • No specific safety issues when CAN008 (200 or 400 mg) was combined with RT and TMZ. PFS rates Cohort 1 Cohort 2 (200 mg; n=3) (400 mg; n=7) • Two patients in Cohort 2 experienced serious adverse e
Slide 14: Hunterase® – The Only ERT Approved for MPSII Launched in China
Hunterase® – The Only ERT Approved for MPSII Launched in China Large untapped MPSII market in China. Patient identification and treatment reimbursement key to unlocking full commercial potential Slide Title Hunterase® (海芮思） Overview of MPS II Hunterase Marketing Strategies Hunterase® is the first an
Slide 15: CAN108 – IBAT Inhibitor for Rare Cholestatic Liver Diseases
CAN108 – IBAT Inhibitor for Rare Cholestatic Liver Diseases A novel, oral, minimally-absorbed agent designed to selectively inhibit IBAT in the ileum and treat rare cholestatic liver diseases, including Slide ALGS, PFIC Title and BA Obtained an exclusive license to develop, manufacture and Mechanism
Slide 16: CAN108 – Clinical Development Plan
CAN108 – Clinical Development Plan Large and robust safety dataset provides strong support for further studies in PFIC and BA Slide Title CAN108 Development Status Pivotal Studies NDA Filing ALGS PFIC Collaboration with Mirum for the BA development of CAN108 ALGS: China NDA potential approval in Q1
Slide 17: CAN106 – Long-acting Anti-C5 Therapy for Complement Disorders
CAN106 – Long-acting Anti-C5 Therapy for Complement Disorders Significant unmet need in treating patients with complement-related disease in China and across the globe Slide Title Mechanism of Action Obtained global rights to develop, manufacture and commercialize CAN106 1 CAN106 binds to the α chai
Slide 18: CAN106 – Phase 1 SAD Topline Results
CAN106 – Phase 1 SAD Topline Results Complete blockade of complement function encourages further studies in patients with PNH Slide Title Mean concentration-time curves of CAN106 by cohort SAD Topline Results Safety • CAN106 was safe and well-tolerated with no drug- related serious adverse events (S
Slide 19: Three-Pronged Gene Therapy Research Strategy
Three-Pronged Gene Therapy Research Strategy In-house gene therapy research to build AAV platform for specific tissue targeting; accelerate development of cutting-edge gene therapy technology by partnering Slide with industryTitle innovators and working with academic experts In-house Research CANbri
Slide 20: Developing Gene Therapies to Treat LSDs
Developing Gene Therapies to Treat LSDs Gene therapy holds the promise to transform treatments for LSDs such as Fabry disease / Pompe disease from chronic to curative Slide Title Application to Lysosomal Storage Diseases (LSDs) LSDs are a group of over 70 diseases that are characterized by lysosomal
Slide 21: CAN103, CAN107, CAN105 and CAN104 – Preclinical Candidates
CAN103, CAN107, CAN105 and CAN104 – Preclinical Candidates Slide Title Global Prevalence Global Prevalence China Prevalence Global Prevalence ~78k ~141k ~120k ~1,789k CAN103 CAN107 CAN105 CAN104 An ERT for Gaucher Disease (GD) A recombinant humanized anti- Under development for the treatment An ERT
Slide 22: Financial Review
Slide Title 04 Financial Review 22
Slide 23: 2021 Financial Highlights
2021 Financial Highlights Slide RMB Million Title 31.2 427.7 160% 290% Revenue R&D Expenses YoY increase of RMB 19.2M YoY increase of RMB 318.0M mainly attributable to the primarily attributable to increased increase of sales from payments made to our licensing 12.0 Hunterase® and Nerlynx® partners,
Slide 24: Outlook
Slide Title 05 Outlook 24
Slide 25: Upcoming Key Milestones and Strategic Imperatives
Upcoming Key Milestones and Strategic Imperatives Slide We expectTitle in the next two years: CAN008 –Phase 2 interim readout in 2023 CAN108 – Potential approval for ALGS in China CAN108 – Potential NDA filing for PFIC in China CAN201 – IND filing to US FDA and plan to start trials in 2024 CAN202 –
Slide 26: Q&A
Slide Title Q&A CANBRIDGE-B, 01228.HK www.canbridgepharma.com
Slide 27: THANK YOU
Slide Title THANK YOU CANBRIDGE-B, 01228.HK Contact: www.canbridgepharma.com WeChat Official Account IR@canbridgepharma.com
Slide 28: Appendix
Slide Title 06 Appendix 28
Slide 29: Income Statement
Income Statement Slide Title Year ended December 31 Revenue RMB’000 2021 2020 YoY increase of RMB 19.2M mainly attributable to the increase of Revenue 31,161 12,032 sales from Hunterase® and Nerlynx® Cost of sales (12,385) (5,154) Research and Development Expenses Gross profit (IFRS Measure) 18,776
Slide 30: Balance Sheet
Balance Sheet Slide Title RMB’000 2021 Year ended December 31 2020 Property, plant and equipment 9,564 4,026 Right-of-use assets 19,978 11,544 Intangible assets 51,269 179,743 Total Non-current Assets 80,811 195,313 Inventories 13,448 553 Trade receivables 9,141 7,040 Prepayments, other receivables
CANbridge Pharmaceuticals — FY2021 Earnings Presentation on 6ix